Nimotuzumab plus chemotherapy before and after pancreatic cancer surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests combining a targeted drug (nimotuzumab) with two chemotherapy drugs (nab-paclitaxel and gemcitabine) before and after surgery for pancreatic cancer that can be surgically removed but has high-risk features or is borderline resectable. The goal is to see if this approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of pancreatic cancer called pancreatic ductal adenocarcinoma (PDAC).
- Your cancer is considered surgically removable (resectable with high-risk factors like high CA19-9, large tumor, or weight loss) or borderline removable (borderline resectable).
- You have not had previous treatment for pancreatic cancer.
- Your blood counts, liver, and kidney function are adequate (your doctor will check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug combination (AG and nimotuzumab) followed by a procedure called irreversible electroporation (IRE) to treat locally advanced pancreatic cancer that hasn't spread. It aims to see if this approach can help patients whose cancer can't be removed by surgery.
This trial tests adding nimotuzumab (a targeted therapy) to standard chemotherapy for people whose pancreatic cancer was completely removed with surgery. The goal is to see if this combination helps prevent the cancer from coming back.
This trial tests combining nimotuzumab with chemotherapy (nab-paclitaxel and gemcitabine) after surgery to prevent pancreatic cancer from returning. It is for people whose tumors have a protein called EGFR, and whose cancer was removed with clear or close margins.
This trial tests adding the immunotherapy drug adebrelimab to standard chemotherapy before surgery for pancreatic cancer that can be removed. The goal is to see if this combination shrinks tumors more effectively.
This trial tests a new targeted drug (HRS-4642) combined with another drug (Nimotuzumab) and two chemotherapy drugs for people with a specific type of pancreatic cancer that has a KRAS G12D mutation. The goal is to see if this combination can help make the tumor smaller and possibly removable by surgery.
This trial tests a new targeted drug (HRS-4642) combined with nimotuzumab and chemotherapy for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. It's for those who haven't had treatment for advanced disease yet.
Hear when a new Pancreatic Cancer, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.